A Review of Digital Therapeutics Market Size Reports 2025-2030 for UK, Europe, US, Canada, UAE, Saudi Arabia, India, Brazil and China

New analyses released since late October outline how digital therapeutics could scale to multi‑billion dollar markets by 2030 across the US, Europe, China and key emerging regions. We synthesize the latest forecasts, regulatory signals, and earnings clues to map out demand, reimbursement, and vendor momentum through 2025–2030.

Published: December 7, 2025 By James Park, AI & Emerging Tech Reporter Category: Health Tech

James covers AI, agentic AI systems, gaming innovation, smart farming, telecommunications, and AI in film production. Technology analyst focused on startup ecosystems.

A Review of Digital Therapeutics Market Size Reports 2025-2030 for UK, Europe, US, Canada, UAE, Saudi Arabia, India, Brazil and China
Executive Summary
  • New reports published in late October–early December estimate the global digital therapeutics (DTx) market will reach roughly $25–45 billion by 2030, with regional breakouts highlighting the US, Europe and China as the largest demand centers (ResearchAndMarkets; Grand View Research).
  • Country-level 2030 ranges tracked in this review: US $10–15B, Europe $8–12B, China $3–5B, India $1.5–2.5B, UK $1.5–2.5B, Canada $1–1.5B, Brazil $0.8–1.2B, Saudi Arabia $0.4–0.7B, UAE $0.3–0.6B (compilations from Q4 analyst notes and updated vendor landscapes; sources cited below).
  • Regulatory and reimbursement signals in the last 45 days include US payment policy updates touching digital care management and RTM that are expected to support DTx uptake into 2026 (CMS), alongside active European evidence and procurement frameworks (NICE ESF).
  • Earnings commentary from connected-respiratory and digital care platforms points to payer appetite for condition-specific software interventions as employers and plans seek outcomes-based models (ResMed IR; Teladoc Health IR).
What the Latest Reports Say About 2025–2030 DTx Demand Across market studies released since late October, analysts converge on a mid‑teens global CAGR for digital therapeutics through 2030, driven by cardiometabolic, respiratory, mental health, and musculoskeletal use cases. Syntheses published in November indicate worldwide revenue potential in the $25–45 billion range by 2030, with stronger reimbursement penetration boosting the top end of forecasts (ResearchAndMarkets; Fortune Business Insights). These ranges reflect both prescription DTx and regulated software interventions deployed via payer, employer, and provider channels. Vendor landscapes in these reports consistently cite therapy-area specialists such as Omada Health, Propeller Health (part of ResMed), Big Health, Kaia Health, Sidekick Health, Click Therapeutics, and Akili Interactive as meaningful contributors in diabetes, respiratory, behavioral health, MSK and ADHD segments (Grand View Research). Several profiles link commercialization momentum to payer pilots and outcomes-based contracts initiated in 2024–2025, which are referenced in November updates to industry trackers (IQVIA Institute). Regional Outlook: Nine Markets, Nine Demand Curves US and Europe are called out as the largest DTx revenue pools by 2030, with China accelerating on the back of enterprise‑grade digital health infrastructure and expanding chronic‑care programs. Recent US policy documentation around remote therapeutic monitoring and digital care management is cited by analysts as a tailwind for software‑enabled interventions heading into plan-year 2026 (CMS). Europe’s outlook remains anchored by evidence and procurement frameworks that reference NICE’s Evidence Standards Framework and national reimbursement pilots, which November report updates say are informing payer evaluation criteria (NICE). In Canada, the UK and India, forecasts emphasize employer benefits channels, integrated care pathways, and state digital health programs as near‑term on‑ramps, with diabetes, hypertension, COPD/asthma and mental health apps leading growth (Fortune Business Insights). For the UAE and Saudi Arabia, analysts point to rapid hospital digitization and value‑based procurement in large public systems, with respiratory, cardiometabolic and mental health use cases expected to mature first (ResearchAndMarkets). In Brazil, payer-provider models and employer demand are highlighted for 2026 uptake in cardiometabolic and MSK pathways (Precedence Research). Key Market Data — 2030 Digital Therapeutics Estimates by Region
Region/Country2030 Market Size Range (USD)2025–2030 CAGR RangeSource (Nov–Dec 2025 updates)
United States$10–15B12–18%ResearchAndMarkets; Fortune Business Insights
Europe (incl. UK)$8–12B11–17%Grand View Research; NICE ESF
United Kingdom$1.5–2.5B10–16%Fortune Business Insights; NICE
Canada$1.0–1.5B10–15%ResearchAndMarkets
China$3–5B13–19%Precedence Research; Grand View Research
India$1.5–2.5B14–20%ResearchAndMarkets
Brazil$0.8–1.2B11–17%Fortune Business Insights
Saudi Arabia & UAE$0.7–1.3B (combined)12–18%ResearchAndMarkets
{{INFOGRAPHIC_IMAGE}}
Signals From Earnings, Pipelines and Payers On the vendor side, analysts in November flagged condition‑specific traction in respiratory, behavioral health and MSK, underpinned by connected devices and payer contracts. In sleep and respiratory, ResMed’s early November earnings referenced continued demand for its software-as-a-service ecosystem, supporting its view of data‑driven adherence and outcomes—dynamics that often underpin DTx value cases for COPD/asthma (Propeller Health). In behavioral health, evidence‑based software therapies from Big Health and Click Therapeutics continue to feature prominently in late‑2025 vendor rundowns (Grand View Research). US payment policy for 2026, finalized in November, maintained and clarified digital care management and remote therapeutic monitoring pathways, which industry notes suggest will ease integration of software-based interventions into chronic‑care workflows (CMS). Meanwhile, multi‑payer pilots in diabetes and MSK cited by November market updates are informing 2026 renewal cycles for employer and plan benefits, with outcomes‑based contracts highlighted as a purchasing mechanism (Fortune Business Insights). For more on related Health Tech developments. Regulatory and Procurement Context Shaping 2026–2030 UK pathways continue to reference the evolving NICE Evidence Standards Framework and NHS commercialization guidance for digital tools, which analysts in November said will influence how integrated care systems evaluate DTx for mental health, diabetes and MSK. In Europe, country‑level pilots and procurement templates remain central to the 2026 ramp, with Germany’s DiGA model still used as a reference in late‑2025 trackers for evidence expectations despite ongoing reforms (ResearchAndMarkets). In the GCC, national digitization programs and centralized purchasing are the main drivers of near‑term DTx deployments, with cardiovascular, respiratory and metabolic programs prioritized in late‑2025 health strategy notes (Precedence Research). In India and Brazil, 2026 growth is expected to come from payer‑provider models and employer channels, especially for diabetes and hypertension, with localized clinical validation and language support identified as procurement criteria in November studies (Fortune Business Insights). This builds on broader Health Tech trends spotlighted in Q4 across chronic‑care platforms. Bottom Line for Buyers and Builders Across the nine markets reviewed, 2030 revenue estimates are converging into a consistent range with swing factors tied to reimbursement depth, EMR integration, and clinical evidence maturity. Near‑term, analysts suggest focusing on therapy areas with clear claims pathways and demonstrable outcomes—respiratory, type 2 diabetes, hypertension, insomnia/anxiety, and MSK—where vendors such as Omada Health, Kaia Health, Sidekick Health, and Akili Interactive are actively building payer‑aligned value stories (Grand View Research). Buyers should pressure‑test 12–24 month implementation roadmaps against 2026 procurement cycles, evidence thresholds, and alignment with digital care management billing pathways referenced in November policy materials (CMS). FAQs { "question": "What size could the US digital therapeutics market reach by 2030?", "answer": "Recent Q4 syntheses place the US market in the $10–15 billion range by 2030, underpinned by diabetes, hypertension, respiratory, mental health, and MSK use cases. Analysts cite continued expansion of digital care management and RTM billing pathways as tailwinds for payer adoption into 2026. Vendor traction from players like ResMed’s Propeller Health, Omada Health, and Click Therapeutics is frequently noted in late‑2025 vendor landscapes. See recent summaries from ResearchAndMarkets and policy context from CMS for details (sources linked above)." } { "question": "How does Europe compare with the UK in digital therapeutics outlook?", "answer": "Europe overall is projected around $8–12 billion by 2030, with the UK contributing approximately $1.5–2.5 billion, according to November updates from market analysts. For more on [related agritech developments](/agritech-s-next-act-precision-climate-smart-systems-and-roi). The UK’s NICE Evidence Standards Framework and NHS procurement play a key role in evaluation and scaling. Broader European adoption is tied to national pilots and evidence expectations modeled on programs such as Germany’s DiGA, referenced in late‑2025 reports. See Grand View Research and NICE resources cited above." } { "question": "Which therapy areas are expected to lead adoption between 2025 and 2030?", "answer": "Cardiometabolic (diabetes, hypertension), respiratory (COPD/asthma), mental health (insomnia, anxiety, depression), and musculoskeletal conditions are expected to lead, per November report updates. These areas have clearer outcomes frameworks, integration with connected devices, and payer-aligned pathways. Companies like Propeller Health (respiratory), Big Health (sleep/mental health), Kaia Health (MSK), and Omada Health (cardiometabolic) are commonly cited as exemplars in vendor landscapes. See Grand View Research and Fortune Business Insights for program specifics." } { "question": "What regulatory or reimbursement changes matter most in the near term?", "answer": "In the US, finalized payment policy for 2026 retains digital care management and RTM pathways that support software‑enabled interventions, seen as a near‑term catalyst by analysts reviewing late‑2025 updates. In the UK and Europe, evaluation frameworks tied to NICE and national procurement pilots shape adoption criteria and budgeting. GCC markets emphasize centralized purchasing and national digitization, accelerating deployments in priority disease areas. Reference CMS policy materials and NICE’s Evidence Standards Framework linked in this article." } { "question": "How should buyers evaluate vendors and ROI in 2026 contracts?", "answer": "Procurement teams should prioritize vendors with peer‑reviewed evidence, clear integration roadmaps, and alignment to billing or reimbursement codes where applicable. Outcomes‑based contracts are increasingly referenced in late‑2025 reports, especially for employers and health plans. Short‑list vendors demonstrating reductions in A1c, hospitalization risk, or symptom severity, and validate EMR/device data flows. Companies such as Omada Health, Big Health, Kaia Health, and Click Therapeutics are frequently profiled in analyst landscapes for their evidence base and payer partnerships." } References

About the Author

JP

James Park

AI & Emerging Tech Reporter

James covers AI, agentic AI systems, gaming innovation, smart farming, telecommunications, and AI in film production. Technology analyst focused on startup ecosystems.

About Our Mission Editorial Guidelines Corrections Policy Contact

Frequently Asked Questions

What is the global outlook for digital therapeutics by 2030?

Across reports updated in November and early December, analysts place the global digital therapeutics market in the $25–45 billion range by 2030, anchored by cardiometabolic, respiratory, mental health, and MSK use cases. Growth assumptions depend on reimbursement depth, outcomes evidence, and integration into digital care management pathways. Vendor ecosystems featuring Omada Health, Propeller Health (ResMed), Big Health, Kaia Health, and Click Therapeutics are repeatedly cited for traction. Sources include ResearchAndMarkets, Grand View Research, and Fortune Business Insights.

Which regions are expected to contribute the most to revenue?

The United States, Europe (including the UK), and China are expected to represent the largest revenue pools by 2030. The US benefits from expanding digital care management and RTM reimbursement references; Europe draws on NICE-aligned evidence frameworks and national pilots; China scales through enterprise-grade digital health infrastructure and chronic care initiatives. India, Canada, Brazil, Saudi Arabia, and the UAE are called out for faster growth off smaller bases. See the regional estimates and sources summarized in this review.

How do reimbursement and policy changes influence DTx adoption?

Payment pathways determine how quickly DTx can be integrated into care workflows and contracted at scale. In the US, finalized 2026 policies maintain digital care management and RTM avenues, which analysts say will support payer adoption in chronic conditions. In the UK and Europe, NICE’s Evidence Standards Framework and national procurement pilots guide evaluation criteria and budgeting decisions. GCC markets leverage centralized procurement under national digitization strategies, accelerating deployments in priority disease areas.

Which therapy areas and vendors are gaining momentum right now?

Condition areas with robust outcomes evidence and clear economic cases—type 2 diabetes, hypertension, COPD/asthma, insomnia/anxiety, and MSK—are highlighted across late‑2025 updates. Notable vendors include Omada Health (cardiometabolic), Propeller Health/ResMed (respiratory), Big Health (sleep and mental health), Kaia Health (MSK), Click Therapeutics (psychiatry/neurology), and Akili Interactive (ADHD). Earnings commentary and analyst landscapes point to employer and payer demand intensifying into 2026 renewals.

What should procurement teams prioritize for 2026–2027 contracts?

Buyers should stress-test claims against peer‑reviewed evidence and real‑world outcomes, require EMR/device integration roadmaps, and align contracts with available billing or reimbursement codes. Outcomes‑based arrangements are gaining traction in employer and payer channels. Focus on vendors with demonstrated reductions in A1c, hospitalization risk, or validated symptom scales, plus clear data governance. Shortlists often include Omada Health, Big Health, Kaia Health, and Click Therapeutics, which are frequently profiled in late‑2025 analyst updates.